NCT00582504

Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine

A Phase 2 Open-Label, Safety and Immunogenicity Study of a Single Dose of Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried, TC-83, NDBR-102, as Primary Immunization in Healthy Adults At Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: U.S. Army Medical Research and Development Command · Federal
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study is designed to determine safety of and immune response to Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried TC-83, NDBR-102 (TC-83).

Conditions

• Venezuelan Equine Encephalomyelitis

Interventions

Type	Name	Description
BIOLOGICAL	VEE TC-83	Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm

Timeline

• Start date: 2007-09-01
• Primary completion: 2021-12-01
• Completion: 2022-06-01
• First posted: 2007-12-28
• Last updated: 2021-02-11

Locations

1 site across 1 country: United States